Literature DB >> 7954444

Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene.

J H Kim1, S H Kim, S L Brown, S O Freytag.   

Abstract

The activation of antiviral drugs as a consequence of thymidine kinase expression has been shown in recent years to have potential as a treatment for malignant tumors. It was hypothesized that the property of the drugs that make them effective against viruses and proliferating cells, namely their ability to interfere with the integrity of the DNA, may be exploited to sensitize cells to radiation damage. The antiviral drug, BVdUrd, structurally a pyrimidine analogue, was found to enhance selectively the radiation cytotoxicity of human tumor cells transduced with the HSV-tk thymidine kinase gene. Human glioma cells from the U-251 lineage transduced with HSV-tk and exposed to 40 micrograms/ml of BVdUrd for 24 h prior to irradiation were more sensitive to radiation compared with control cells under the same conditions; the sensitization enhancement ratio was 1.9. The results suggest that the addition of radiation will improve the effectiveness of HSV-tk gene therapy for the treatment of brain tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954444

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

2.  Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells.

Authors:  S Kumar; S L Brown; A Kolozsvary; S O Freytag; J H Kim
Journal:  J Neurooncol       Date:  2008-07-02       Impact factor: 4.130

3.  Effect of gene therapy with the herpes simplex virus-thymidine kinase gene on hepatic metastasis in murine colon cancer.

Authors:  S Hayashi; N Emi; I Yokoyama; K Uchida; H Takagi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 4.  The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.

Authors:  S S Andreansky; B He; G Y Gillespie; L Soroceanu; J Markert; J Chou; B Roizman; R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir.

Authors:  S H Kim; J H Kim; A Kolozsvary; S L Brown; S O Freytag
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

6.  Clinical experience with gene therapy for the treatment of prostate cancer.

Authors:  Matthew A Stanizzi; Simon J Hall
Journal:  Rev Urol       Date:  2007

Review 7.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

8.  Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.

Authors:  M Ahn; S-J Lee; X Li; J A Jiménez; Y-P Zhang; K-H Bae; Y Mohammadi; C Kao; T A Gardner
Journal:  Cancer Gene Ther       Date:  2008-09-05       Impact factor: 5.987

9.  Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.

Authors:  L C Pederson; S M Vickers; D J Buchsbaum; S R Kancharla; M S Mayo; D T Curiel; M A Stackhouse
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.267

10.  Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure.

Authors:  Branka Stancevic; Nira Varda-Bloom; Jin Cheng; John D Fuller; Jimmy A Rotolo; Mónica García-Barros; Regina Feldman; Shyam Rao; Ralph R Weichselbaum; Dror Harats; Adriana Haimovitz-Friedman; Zvi Fuks; Michel Sadelain; Richard Kolesnick
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.